Get the Stockscreener App
7.31
1.62%
-0.12
Actuate Therapeutics Inc stock is traded at $7.31, with a volume of 63,168.
It is down -1.62% in the last 24 hours and up +13.86% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$7.43
Open:
$7.43
24h Volume:
63,168
Relative Volume:
0.91
Market Cap:
$169.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.94%
1M Performance:
+13.86%
6M Performance:
-19.76%
1Y Performance:
-16.65%
1-Day Range:
$7.23
$7.50
1-Week Range:
$6.68
$7.787
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
7.31 | 172.70M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Will Actuate Therapeutics Inc. stock see PE expansionInsider Selling & Daily Chart Pattern Signal Reports - Newser
Why Actuate Therapeutics Inc. stock is a must watch in 2025Forecast Cut & AI Based Buy and Sell Signals - Newser
Actuate Therapeutics enters $100 million at-the-market sales agreement - Investing.com
Actuate Therapeutics Signs $100M Sales Agreement - TipRanks
Actuate Therapeutics Inc enters at the market issuance sales agreement with B. Riley and Craig-HallumSEC filing - marketscreener.com
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Zacks Investment Research
Why Actuate Therapeutics Inc. stock is recommended by analystsJuly 2025 Analyst Calls & Verified Technical Trade Signals - BỘ NỘI VỤ
What risks investors should watch in Actuate Therapeutics Inc. stockOptions Play & Weekly Setup with ROI Potential - BỘ NỘI VỤ
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st
BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU - Defense World
What analysts say about Actuate Therapeutics Inc stockTrade Execution Strategies & Daily Tips From Top Market Analysts - earlytimes.in
Will Upside Catalysts Materialize for Prime Industries Limited in YEARHigh Frequency Trading Trends & Free Unlock Rapid Growth Potential - earlytimes.in
HC Wainwright Has Bullish Estimate for ACTU FY2025 Earnings - Defense World
Why Actuate Therapeutics Inc. stock is in analyst buy zoneEarnings Trend Report & Verified Entry Point Signals - newser.com
Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating - TipRanks
HC Wainwright & Co. Reiterates Actuate Therapeutics (ACTU) Buy Recommendation - Nasdaq
How Actuate Therapeutics Inc. stock compares to market leadersEarnings Overview Report & Expert Approved Momentum Ideas - newser.com
Using R and stats models for Actuate Therapeutics Inc. forecastingRate Hike & Fast Gaining Stock Reports - newser.com
Strategies to average down on Actuate Therapeutics Inc.Quarterly Risk Review & Safe Capital Growth Stock Tips - newser.com
How Actuate Therapeutics Inc. stock benefits from tech adoptionTrade Volume Summary & Long-Term Growth Plans - newser.com
Advanced analytics toolkit walkthrough for Actuate Therapeutics Inc.July 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
Is it time to cut losses on Actuate Therapeutics Inc.July 2025 Update & High Yield Stock Recommendations - newser.com
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation - Yahoo Finance
What indicators show strength in Actuate Therapeutics Inc.July 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.5% on Better-Than-Expected Earnings - Defense World
Analysts Offer Insights on Healthcare Companies: Vicarious Surgical (RBOT) and Intensity Therapeutics, Inc. (INTS) - The Globe and Mail
Actuate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA), Janux Therapeutics Inc (JANX) and Eledon Pharmaceuticals (ELDN) - The Globe and Mail
What’s next for Actuate Therapeutics Inc. stock priceJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Real time scanner hits for Actuate Therapeutics Inc. explained2025 Sector Review & Precise Swing Trade Alerts - newser.com
Is Actuate Therapeutics Inc. building a consolidation base2025 Trading Recap & AI Forecast for Swing Trade Picks - newser.com
Myelofibrosis Market is Expected to Flourish in 7MM, Expanding - openPR.com
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):